Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine
June 19, 2017 Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine designed to help protect against Group B Streptococcus (GBS) infection. An estimated 10 to 30... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 19, 2017 Category: Pharmaceuticals Source Type: clinical trials

A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age
Condition:   Group B Streptococcal Infections Interventions:   Biological: Multivalent group B streptococcus vaccine;   Biological: Placebo Sponsor:   Pfizer Not yet recruiting - verified May 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2017 Category: Research Source Type: clinical trials